114 related articles for article (PubMed ID: 17489737)
1. Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers.
Carney WP
Expert Rev Mol Diagn; 2007 May; 7(3):309-19. PubMed ID: 17489737
[TBL] [Abstract][Full Text] [Related]
2. Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab).
Ho D; Huang J; Chapman JW; Leitzel K; Ali SM; Shepherd L; Parulekar WR; Ellis CE; Crescnzo RJ; Zhu L; Virk S; Nomikos D; Aparicio S; Gelmon KA; Carney WP; Lipton A
Breast Cancer Res Treat; 2017 Aug; 164(3):571-580. PubMed ID: 28484925
[TBL] [Abstract][Full Text] [Related]
3. Hidden HER-2/neu-positive breast cancer: how to maximize detection.
Carney WP
IDrugs; 2009 Apr; 12(4):238-42. PubMed ID: 19350468
[TBL] [Abstract][Full Text] [Related]
4. Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer.
Swinson DE; Cox G; O'Byrne KJ
Br J Cancer; 2004 Oct; 91(7):1301-7. PubMed ID: 15365565
[TBL] [Abstract][Full Text] [Related]
5. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.
Atkins M; Regan M; McDermott D; Mier J; Stanbridge E; Youmans A; Febbo P; Upton M; Lechpammer M; Signoretti S
Clin Cancer Res; 2005 May; 11(10):3714-21. PubMed ID: 15897568
[TBL] [Abstract][Full Text] [Related]
6. Carbonic anhydrase IX expression is more predictive than prognostic in breast cancer.
Span PN; Bussink J; De Mulder PH; Sweep FC
Br J Cancer; 2007 Apr; 96(8):1309; author reply 1310. PubMed ID: 17387339
[No Abstract] [Full Text] [Related]
7. ERBB1/EGFR and ERBB2 (HER2/neu)--targeted therapies in cancer and cardiovascular system with cardiovascular drugs.
Patanè S
Int J Cardiol; 2014 Oct; 176(3):1301-3. PubMed ID: 25131912
[No Abstract] [Full Text] [Related]
8. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
9. Biomarker discovery in urogenital cancer.
Said J
Biomarkers; 2005 Nov; 10 Suppl 1():S83-6. PubMed ID: 16298916
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
[TBL] [Abstract][Full Text] [Related]
11. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.
Bui MH; Seligson D; Han KR; Pantuck AJ; Dorey FJ; Huang Y; Horvath S; Leibovich BC; Chopra S; Liao SY; Stanbridge E; Lerman MI; Palotie A; Figlin RA; Belldegrun AS
Clin Cancer Res; 2003 Feb; 9(2):802-11. PubMed ID: 12576453
[TBL] [Abstract][Full Text] [Related]
12. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
Wainberg ZA; Anghel A; Desai AJ; Ayala R; Luo T; Safran B; Fejzo MS; Hecht JR; Slamon DJ; Finn RS
Clin Cancer Res; 2010 Mar; 16(5):1509-19. PubMed ID: 20179222
[TBL] [Abstract][Full Text] [Related]
13. Expression of hypoxia-related tissue factors in astrocytic gliomas. A multivariate survival study with emphasis upon carbonic anhydrase IX.
Korkolopoulou P; Perdiki M; Thymara I; Boviatsis E; Agrogiannis G; Kotsiakis X; Angelidakis D; Rologis D; Diamantopoulou K; Thomas-Tsagli E; Kaklamanis L; Gatter K; Patsouris E
Hum Pathol; 2007 Apr; 38(4):629-38. PubMed ID: 17367605
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
15. Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion.
Robertson N; Potter C; Harris AL
Cancer Res; 2004 Sep; 64(17):6160-5. PubMed ID: 15342400
[TBL] [Abstract][Full Text] [Related]
16. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma.
Leibovich BC; Sheinin Y; Lohse CM; Thompson RH; Cheville JC; Zavada J; Kwon ED
J Clin Oncol; 2007 Oct; 25(30):4757-64. PubMed ID: 17947723
[TBL] [Abstract][Full Text] [Related]
17. Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors.
Sobhanifar S; Aquino-Parsons C; Stanbridge EJ; Olive P
Cancer Res; 2005 Aug; 65(16):7259-66. PubMed ID: 16103077
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer.
Hussain SA; Ganesan R; Reynolds G; Gross L; Stevens A; Pastorek J; Murray PG; Perunovic B; Anwar MS; Billingham L; James ND; Spooner D; Poole CJ; Rea DW; Palmer DH
Br J Cancer; 2007 Jan; 96(1):104-9. PubMed ID: 17213826
[TBL] [Abstract][Full Text] [Related]
19. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma.
Thomas DG; Giordano TJ; Sanders D; Biermann S; Sondak VK; Trent JC; Yu D; Pollock RE; Baker L
Cancer; 2005 Feb; 103(4):830-8. PubMed ID: 15641030
[TBL] [Abstract][Full Text] [Related]
20. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
Sandri MT; Johansson HA; Zorzino L; Salvatici M; Passerini R; Maisonneuve P; Rocca A; Peruzzotti G; Colleoni M
Cancer; 2007 Aug; 110(3):509-17. PubMed ID: 17559147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
